Aims and objectives

The ESCMID Study Group for Host and Microbiota Interactions (ESGHAMI) is leading the way in bridging diagnostics, clinical research, and scientific studies across the relatively new field of microbiota research in Europe. The group seeks to understand the clinical significance of host-microbiota associated diseases and health, and explore relevant therapeutic interventions. Their research covers:

  • Intestinal, urogenital, respiratory, and skin microbiota of both humans and animals
  • Interactions of microbiota with the host immune response

Activities and resources

How can the gut microbiome be targeted to fight multidrug-resistant organisms? 

Davido B, Merrick B, Kuijper E, Benech N, Biehl LM, Corcione S; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Host and Microbiota Interactions (ESGHAMI). Lancet Microbe. 2025 Aug;6(8):101063

Go to publication


Nonantimicrobial therapies for recurrent urinary tract infection in women: is there a place for faecal microbiota transfer? 

Cassir N, Ghani R, Biehl LM, Graells T, Kuijper EJ, Mullish BH, Marchesi JR, Benech N; ESCMID Study Group for Host and Microbiota Interactions (ESGHAMI). Clin Microbiol Infect. 2025 Dec;31(12):1985-1992

Go to publication


MRSA in the community-time to take action.

Goodman AL, Lina G, Kuijper EJ. Clin Microbiol Infect. 2024 Nov 20:S1198-743X(24)00536-6

Go to publication


Update on microbiota-derived therapies for recurrent Clostridioides difficile infections.

Benech N, Barbut F, Fitzpatrick F, Krutova M, Davies K, Druart C, Cordaillat-Simmons M, Heritage J, Guery B, Kuijper E; ESGCD and ESGHAMI.  Clin Microbiol Infect. 2024 Apr;30(4):462-468. 

Go to publication


Which trial do we need? A sequential multiple assignment randomized trial to determine the optimal Clostridioides difficile treatment sequence.

van Prehn J, van Werkhoven CH, Skinner AM, Guery B, Dubberke ER, Kuijper EJ. Clinical Microbiology and Infection 2024;30(2):165–169.

Go to publication


Bacteriophage therapy in humans.

Nir-Paz R, Kuijper EJ. Clin Microbiol Infect. 2023;29(6):679–681.

Go to publication


Update on Microbiota-derived therapies for recurrent Clostridioides difficile infections, 2023.

Benech N, Barbut N, Fitzpatrick F, Krutova M, Davies K, Druart C, Cordaillat-Simmons M, hHeritage J, Guery B, Kuijper E. Clinical Microbiology and Infection. 2023:S1198-743X(23)00597-9.

Go to publication


Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection.

van Prehn J, Fitzpatrick F, Kuijper EJ. Lancet Gastroenterol Hepatol. 2022;7(12):1083–1091.

Go to publication

27

Mar 26
27 March 2026, 13:00 CET
Webinar

26

Jun 25
26 June 2025, 16:00 CET
Webinar

13

May 25
13 May 2025, 17:00 CET
Webinar

Executive Committee

  Ed J. Kuijper

Ed J. Kuijper

Treasurer
Leiden University Medical Centre
Leiden, Netherlands
  Nicolas Benech

Nicolas Benech

Chair
Hospices Civils de Lyon
Lyon, France
  Silvia Corcione

Silvia Corcione

Secretary
University of Turin
Turin, Italy

Contact

If you have questions or comments for our study group, we warmly invite you to contact us!

Contact form